Seminars in Oncology Nursing
Volume 22, Issue 4 , Pages 257-266 , November 2006

Radioimmunotherapy for Non-Hodgkin’s Lymphoma

  • Pat Liebenguth

      Affiliations

    • Corresponding Author InformationAddress correspondence to Pat Liebenguth, RN, OCN®, Department of Radiation Oncology, Baptist Hospital, 1717 North E St, Suite 134, Pensacola, FL 32501
    • ,
  • Susan Vogt Temple

References 

  1. Kaminski MS, Radford JA, Gregory SA, et al. Retreatment with 131I tositumomab in patients with non-Hodgkin’s lymphoma who had previously responded to 131I tositumomab. J Clin Oncol. 2005;23:7985–7993
  2. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2001;19:3918–3928
  3. DeNardo GL. Treatment of non-Hodgkin’s lymphoma (NHL) with radiolabeled antibodies (mAbs). Semin Nucl Med. 2005;35:202–211
  4. Forero A, LoBuglio AF. History of antibody therapy for non-Hodgkin’s lymphoma. Semin Oncol. 2003;30(suppl 17):1–5
  5. Battiato LA, Wheeler VS. Biologic and targeted therapy. In:  Yarbro CH,  Frogge MH,  Goodman M editor. Cancer Nursing Principles and Practice. Ed 6. Sudbury, MA: Jones and Bartlett; 2005;p. 510–558
  6. Maloney DG. Concepts in radiotherapy and immunotherapy: Anti-CD20 mechanisms of action and targets. Semin Oncol. 2005;32(suppl 1):S19–S26
  7. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res. 1999;5:611–615
  8. Horning SJ. Future directions in radioimmunotherapy for B-cell lymphoma. Semin Oncol. 2003;30(suppl 17):29–43
  9. Davies AJ. A review of tositumomab and 1131 tositumomab radioimmunotherapy for the treatment of follicular lymphoma. Expert Opin Biol Ther. 2005;5:577–588
  10. Hernandez MC, Knox SJ. Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin). Semin Oncol. 2003;30(suppl 17):6–10
  11. Zevalin [package insert]. Cambridge, MA: Biogen Idec; 2005;
  12. Bexxar [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2005;
  13. Rituxan package insert. South San Francisco, CA: Genentech; 2005;
  14. Wahl RL. Tositumomab and 131I therapy in non-Hodgkin’s lymphoma. J Nucl Med. 2005;46(suppl):128S–140S
  15. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;10:2453–2463
  16. Cardarelli PM, Quinn M, Buckman D, et al. Binding to CD20 by anti-B1 antibody or F(ab’)2 is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother. 2002;51:15–24
  17. Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol. 2005;23:712–719
  18. Davies AJ, Rohatiner AZS, Howell S, et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2004;22:1469–1479
  19. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine 131I Tositumomab for relapsed or refractory B-cell non-Hodgkin’s lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259–1266
  20. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2000;18:1316–1323
  21. Kaminski MS, Tuck M, Estes J, et al. 131I-Tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;353:441–449
  22. Press OW, Unger J, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine 131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: Five year follow up of Southwest Oncology Group protocol S9911. J Clin Oncol. 2006;25:4143–4149
  23. Vose JM, Bierman PJ, Enke C, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:461–467
  24. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:3262–3269
  25. Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long term follow-up of a phase 1/2 study. Blood. 2004;103:4429–4431
  26. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin’s lymphoma and mild thrombocytopenia: A phase II multicenter trial. Blood. 2002;99:4336–4342
  27. Gregory SA. Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin). Semin Oncol. 2003;30(suppl 17):17–22
  28. Hendrix C. Radiation safety with yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy. Semin Oncol Nurs. 2004;20(suppl 1):14–19
  29. Forero A, Meredith RF, Khazaeli MB, et al. A novel monoclonal antibody design for radioimmunotherapy. Cancer Biother Radiopharm. 2003;18:751–759
  30. Meredith RF, Alvarez RD, Partridge EE, et al. Intraperitoneal radioimmunochemotherapy of ovarian cancer: A phase I study. Cancer Biother Radiopharm. 2001;16:305–315
  31. Akabani G, Reardon DA, Coleman RE, et al. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with gliomas: A phase II study. J Nucl Med. 2005;46:1042–1051
  32. Bander NH, Trabulsi EJ, Kostakoglu L, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol. 2003;170:1717–1721
  33. Milowski MI, Nanus DM, Kostakoglu L, et al. Phase I trial of 90Y-labeled antiprostate specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol. 2001;22:2522–2531
  34. Bander NH, Miowski MI, Nanus DM, et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23:4591–4601
  35. Chen S, Beilei L, Hong Xie, et al. Phase I clinical trial of targeted therapy using 131I hepama-1 mab in patients with hepatocellular carcinoma. Cancer Biother Radiopharm. 2004;19:589–600
  36. Buck RH, Robert F, Meredith RF, et al. Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non–small cell lung cancer. Proc Am Assoc Cancer Res. 2000;41:634;(abstr)
  37. Robert F, Busby EM, LoBuglio AF. Chemotherapy tolerance after radioimmunotherapy with 90Y-CC49 monoclonal antibody in patients with advanced non–small cell lung cancer: Clinical effects and hematologic toxicity. Cancer Biother Radiopharm. 2003;18:317–325
  38. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46(suppl 1):62S–66S
  39. DeNardo S. Radioimmunodetection and therapy of breast cancer. Semin Nucl Med. 2005;35:143–151
  40. Goldenberg DM, Sharkey RM, Paganelli G, et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006;24:823–834

PII: S0749-2081(06)00098-2

doi: 10.1016/j.soncn.2006.07.008

Seminars in Oncology Nursing
Volume 22, Issue 4 , Pages 257-266 , November 2006

Article Tools

* Image Usage & Resolution